Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2014

01.08.2014

Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP)

verfasst von: Rongxin Yao, Ying Lin, Qianqian Li, Xieming Zhou, Xiahui Pan, Yunhua Bao, Muqing He, Baoling Zhu, Wenjian Guo, Xiaoji Lin, Limin Jin

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Abnormal cellular immunity induced by deranged Th1/Th2 profile has been revealed to play a critical role in the pathogenesis of immune thrombocytopenic purpura (ITP). Correction of the shifted Th1/Th2 balance represents a potential therapeutic approach to treat ITP. Here, we investigated the effects of IL-11 on the restoration of Th1/Th2 balance in the peripheral blood mononuclear cells (PBMCs) isolated from adult ITP patients. As shown here, we observed a higher ratio of T-bet/GATA-3 gene expression by quantitative real-time PCR in the PBMCs from ITP patients, consistent with the presence of an abnormally high Th1/Th2 ratio. Remarkably, upon IL-11 treatment, a reversal of T-bet/GATA-3 ratio in ITP was achieved and was shown to be responsible for the restoration of Th1/Th2 balance, with IL-11 at 100 ng/ml demonstrating the highest efficiency. T-bet and GATA-3 are the two transcriptional factors that have been indicated to be the master regulators for Th1 and Th2 lineage commitment, respectively. In the presence of 100 ng/ml IL-11, GATA-3 transcript abundance rose up to ~85-fold of that measured in untreated cells, whereas T-bet transcripts were lowered merely to ~41 %, suggesting that GATA-3 was the major contributor for the reversal of T-bet/GATA-3 ratio. Thus, our findings may very well encourage the development of novel medicines that specifically target and correct the T-bet/GATA-3 imbalance identified in ITP.
Literatur
1.
Zurück zum Zitat McMillan R (2007) The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 44(4 Suppl 5):S3–S11PubMedCrossRef McMillan R (2007) The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 44(4 Suppl 5):S3–S11PubMedCrossRef
3.
Zurück zum Zitat Johnsen J (2011) Pathogenesis in immune thrombocytopenia: new insights. Hematol Am Soc Hematol Educ Program 2012:306–312 Johnsen J (2011) Pathogenesis in immune thrombocytopenia: new insights. Hematol Am Soc Hematol Educ Program 2012:306–312
4.
Zurück zum Zitat Olsson B, Andersson PO, Jernas M et al (2003) T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9(9):1123–1124PubMedCrossRef Olsson B, Andersson PO, Jernas M et al (2003) T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9(9):1123–1124PubMedCrossRef
5.
Zurück zum Zitat Zhang F, Chu X, Wang L et al (2006) Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 76(5):427–431PubMedCrossRef Zhang F, Chu X, Wang L et al (2006) Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 76(5):427–431PubMedCrossRef
6.
Zurück zum Zitat Zhang J, Ma D, Zhu X et al (2009) Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica 94(9):1326–1329PubMedCentralPubMedCrossRef Zhang J, Ma D, Zhu X et al (2009) Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica 94(9):1326–1329PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Sakakura M, Wada H, Tawara I et al (2007) Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120(2):187–193PubMedCrossRef Sakakura M, Wada H, Tawara I et al (2007) Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120(2):187–193PubMedCrossRef
8.
Zurück zum Zitat Yu J, Heck S, Patel V et al (2008) Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112(4):1325–1328PubMedCentralPubMedCrossRef Yu J, Heck S, Patel V et al (2008) Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112(4):1325–1328PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Hu Y, Ma DX, Shan NN et al (2011) Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS One 6(10):e26522PubMedCentralPubMedCrossRef Hu Y, Ma DX, Shan NN et al (2011) Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS One 6(10):e26522PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Hu Y, Li H, Zhang L et al (2012) Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Hum Immunol 73(6):629–635PubMedCrossRef Hu Y, Li H, Zhang L et al (2012) Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Hum Immunol 73(6):629–635PubMedCrossRef
11.
Zurück zum Zitat Wang T, Zhao H, Ren H et al (2005) Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 90(7):914–923PubMed Wang T, Zhao H, Ren H et al (2005) Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 90(7):914–923PubMed
12.
Zurück zum Zitat Panitsas FP, Theodoropoulou M, Kouraklis A et al (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103(7):2645–2647PubMedCrossRef Panitsas FP, Theodoropoulou M, Kouraklis A et al (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103(7):2645–2647PubMedCrossRef
13.
Zurück zum Zitat Guo C, Chu X, Shi Y et al (2007) Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 27(6):557–562PubMedCrossRef Guo C, Chu X, Shi Y et al (2007) Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 27(6):557–562PubMedCrossRef
14.
Zurück zum Zitat Shan NN, Ji XB, Wang X et al (2011) In vitro recovery of Th1/Th2 balance in PBMCs from patients with immune thrombocytopenia through the actions of IL-18BPa/Fc. Thromb Res 128(6):e119–e124PubMedCrossRef Shan NN, Ji XB, Wang X et al (2011) In vitro recovery of Th1/Th2 balance in PBMCs from patients with immune thrombocytopenia through the actions of IL-18BPa/Fc. Thromb Res 128(6):e119–e124PubMedCrossRef
15.
Zurück zum Zitat Shier P, Hofstra CL, Ma XJ et al (2000) Tbt-1, a new T-box transcription factor induced in activated Th1 and CD8+ T cells. Immunogenetics 51(10):771–778PubMedCrossRef Shier P, Hofstra CL, Ma XJ et al (2000) Tbt-1, a new T-box transcription factor induced in activated Th1 and CD8+ T cells. Immunogenetics 51(10):771–778PubMedCrossRef
16.
Zurück zum Zitat Szabo SJ, Kim ST, Costa GL et al (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100(6):655–669PubMedCrossRef Szabo SJ, Kim ST, Costa GL et al (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100(6):655–669PubMedCrossRef
17.
Zurück zum Zitat Zhang DH, Cohn L, Cohn L, Ray PB et al (1997) Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 272(34):21597–21603PubMedCrossRef Zhang DH, Cohn L, Cohn L, Ray PB et al (1997) Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 272(34):21597–21603PubMedCrossRef
18.
Zurück zum Zitat Ouyang W, Ranganath SH, Weindel K et al (1998) Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 9(5):745–755PubMedCrossRef Ouyang W, Ranganath SH, Weindel K et al (1998) Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 9(5):745–755PubMedCrossRef
19.
Zurück zum Zitat Farrar JD, Ouyang W, Lohning M, Assenmacher M, Radbruch A, Kanagawa O et al (2001) An instructive component in T helper cell type 2 (Th2) development mediated by GATA-3. J Exp Med 193(5):643–650PubMedCentralPubMedCrossRef Farrar JD, Ouyang W, Lohning M, Assenmacher M, Radbruch A, Kanagawa O et al (2001) An instructive component in T helper cell type 2 (Th2) development mediated by GATA-3. J Exp Med 193(5):643–650PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Chakir H, Wang H, Lefebvre DE et al (2003) T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 278(1–2):157–169PubMedCrossRef Chakir H, Wang H, Lefebvre DE et al (2003) T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 278(1–2):157–169PubMedCrossRef
21.
Zurück zum Zitat Paul SR, Bennett F, Calvetti JA et al (1990) Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 87(19):7512–7516PubMedCentralPubMedCrossRef Paul SR, Bennett F, Calvetti JA et al (1990) Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 87(19):7512–7516PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Vadhan-Raj S (2009) Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 46(1 Suppl 2):S26–S32PubMedCrossRef Vadhan-Raj S (2009) Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 46(1 Suppl 2):S26–S32PubMedCrossRef
23.
Zurück zum Zitat Schwertschlag US, Trepicchio WL, Dykstra KH et al (1999) Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 13(9):1307–1315PubMedCrossRef Schwertschlag US, Trepicchio WL, Dykstra KH et al (1999) Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 13(9):1307–1315PubMedCrossRef
24.
Zurück zum Zitat Trepicchio WL, Ozawa M, Walters IB et al (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104(11):1527–1537PubMedCentralPubMedCrossRef Trepicchio WL, Ozawa M, Walters IB et al (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104(11):1527–1537PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Moreland L, Gugliotti R, King K et al (2001) Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 3(4):247–252PubMedCentralPubMedCrossRef Moreland L, Gugliotti R, King K et al (2001) Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 3(4):247–252PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Qin L, Yuan Z, Du XJ, Ma XH (2008) Curative effect of rhIL-11 on 26 patients with chromic idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(5):1219–1221PubMed Qin L, Yuan Z, Du XJ, Ma XH (2008) Curative effect of rhIL-11 on 26 patients with chromic idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(5):1219–1221PubMed
28.
Zurück zum Zitat Zhang XL, Cheng XZ, Ye X, Shi XJ (2010) Therapeutic effect of interleukin-11 on thrombocytopenia in patients with hematologic malignancies after chemotherapy. Zhonghua Zhong Liu Za Zhi 32(9):713–715PubMed Zhang XL, Cheng XZ, Ye X, Shi XJ (2010) Therapeutic effect of interleukin-11 on thrombocytopenia in patients with hematologic malignancies after chemotherapy. Zhonghua Zhong Liu Za Zhi 32(9):713–715PubMed
29.
Zurück zum Zitat Ragni MV, Jankowitz RC, Jaworski K et al (2011) Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost 106(4):641–645PubMedCentralPubMedCrossRef Ragni MV, Jankowitz RC, Jaworski K et al (2011) Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost 106(4):641–645PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Feinglass S, Deodhar A (2001) Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11. Arthritis Rheum 44(1):170–175PubMedCrossRef Feinglass S, Deodhar A (2001) Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11. Arthritis Rheum 44(1):170–175PubMedCrossRef
31.
Zurück zum Zitat Fontana V, Dudkiewicz P, Jy W et al (2008) Interleukin-11 for treatment of hepatitis C-associated ITP. Acta Haematol 119(2):126–132PubMedCrossRef Fontana V, Dudkiewicz P, Jy W et al (2008) Interleukin-11 for treatment of hepatitis C-associated ITP. Acta Haematol 119(2):126–132PubMedCrossRef
32.
Zurück zum Zitat Bussel JB, Mukherjee R, Stone AJ (2001) A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 66(3):172–177PubMedCrossRef Bussel JB, Mukherjee R, Stone AJ (2001) A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 66(3):172–177PubMedCrossRef
33.
Zurück zum Zitat Curti A, Ratta M, Corinti S et al (2001) Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood 97(9):2758–2763PubMedCrossRef Curti A, Ratta M, Corinti S et al (2001) Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood 97(9):2758–2763PubMedCrossRef
34.
Zurück zum Zitat Hill GR, Cooke KR, Teshima T et al (1998) Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 102(1):115–123PubMedCentralPubMedCrossRef Hill GR, Cooke KR, Teshima T et al (1998) Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 102(1):115–123PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Ji N, Sosa RA, Forsthuber TG (2011) More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases. Immunotherapy 3(3):435–441PubMedCentralPubMedCrossRef Ji N, Sosa RA, Forsthuber TG (2011) More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases. Immunotherapy 3(3):435–441PubMedCentralPubMedCrossRef
Metadaten
Titel
Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP)
verfasst von
Rongxin Yao
Ying Lin
Qianqian Li
Xieming Zhou
Xiahui Pan
Yunhua Bao
Muqing He
Baoling Zhu
Wenjian Guo
Xiaoji Lin
Limin Jin
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2014
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-1036-3

Weitere Artikel der Ausgabe 2/2014

Journal of Thrombosis and Thrombolysis 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.